Health and Healthcare
Johnson & Johnson Slides By With Q2 Earnings
Published:
Last Updated:
When Johnson & Johnson (NYSE: JNJ) reported its most recent quarterly results before the markets opened on Tuesday, the pharmaceutical giant said it had $2.58 in earnings per share (EPS) and $20.6 billion in revenue for its second quarter. The consensus estimates had called for $2.46 in EPS and $20.29 billion in revenue. In the same period of last year, it posted EPS of $2.10 on $20.83 billion in revenue.
Consumer worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 2.3% year over year to $3.54 billion. This was driven by beauty products and over-the-counter products, including upper respiratory and analgesic products.
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 4.4% to $10.53 billion.
Worldwide Medical Devices operational sales, excluding the net impact of acquisitions and divestitures, grew 3.2% to $6.49 billion. This was driven by the growth of electrophysiology products in the Interventional Solutions business, endocutters and international energy products in the Advanced Surgery business.
Alex Gorsky, board chair and chief executive, commented:
We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses. Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. I am proud of our talented colleagues across Johnson & Johnson who continue to deliver significant healthcare advances to improve the lives of patients and consumers around the world.
Shares of Johnson & Johnson traded down 1.5% to $132.58 Tuesday morning, in a 52-week range of $121.00 to $148.99. The consensus price target is $149.17.
24/7 Wall St.The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
